This Article Full Text Full Text (PDF) All Versions of this Article: 39/7/2029    most recent STROKEAHA.107.503458v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, J.-M. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Li, J.-M. Articles by Horiuchi, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections ACE/Angiotension receptors Cerebrovascular disease/stroke Acute Cerebral Infarction Brain Circulation and Metabolism Other Stroke Treatment - Medical Endothelium/vascular type/nitric oxide

(Stroke. 2008;39:2029.)
© 2008 American Heart Association, Inc.

Original Contributions

Temporary Pretreatment With the Angiotensin II Type 1 Receptor Blocker, Valsartan, Prevents Ischemic Brain Damage Through an Increase in Capillary Density

Jian-Mei Li, MD, PhD; Masaki Mogi, MD, PhD; Jun Iwanami, MS; Li-Juan Min, MD, PhD; Kana Tsukuda, BS; Akiko Sakata, MD; Teppei Fujita, MD; Masaru Iwai, MD, PhD Masatsugu Horiuchi, MD, PhD

From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan.

Correspondence to Masatsugu Horiuchi, MD, PhD, FAHA Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Tohon, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

Background and Purpose— We investigated the effect of temporary treatment with a nonhypotensive dose of valsartan on ischemic brain damage in C57BL/6 mice.

Methods— We separated the mice into 3 groups of valsartan treatment before middle cerebral artery (MCA) occlusion: (1) for 4 weeks: Val (2W, 2W); (2) for 2 weeks followed by its cessation for 2 weeks: Val (2W, -); and (3) no treatment for 4 weeks: Val (-, -).

Results— Ischemic volume, DNA damage, superoxide production, and mRNA levels of monocyte chemoattractant protein-1 and tumor necrosis factor- on the ipsilateral side after 24 hours of MCA occlusion were significantly reduced in both Val (2W, 2W) and Val (2W, -) mice compared with those in Val (-, -) mice, whereas these parameters were larger in Val (2W, -) mice than in Val (2W, 2W) mice. Moreover, mice in both the Val (2W, 2W) and Val (2W, -) groups exhibited an increase in cerebral blood flow in the peripheral territory of the MCA 1 hour after MCA occlusion, with increases in endothelial nitric oxide synthase activation and nitric oxide production. Before MCA occlusion, treatment with valsartan did not influence superoxide production or mRNA levels of monocyte chemoattractant protein-1 and tumor necrosis factor- in the brain. However, the capillary density in the brain in both Val (2W, 2W) and Val (2W, -) mice was increased before MCA occlusion.

Conclusions— Our results suggest that temporary valsartan treatment could protect against ischemic brain damage even after its cessation, at least in part due to an increase in capillary density.

Key Words: angiotensin II type 1 receptor blocker • capillary density • cerebral blood flow • oxidative stress • stroke

This article has been cited by other articles:

				S. Chen, G. Li, W. Zhang, J. Wang, C. D. Sigmund, J. E. Olson, and Y. Chen Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1526 - R1531. [Abstract] [Full Text] [PDF]

				K. Tsukuda, M. Mogi, J. Iwanami, L.-J. Min, A. Sakata, F. Jing, M. Iwai, and M. Horiuchi Cognitive Deficit in Amyloid-{beta}-Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-{gamma} Activation Hypertension, October 1, 2009; 54(4): 782 - 787. [Abstract] [Full Text] [PDF]

				A. P. Mecca, T. E. O'Connor, M. J. Katovich, and C. Sumners Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion Exp Physiol, August 1, 2009; 94(8): 937 - 946. [Abstract] [Full Text] [PDF]

				A. Kozak, A. Ergul, A. B. El-Remessy, M. H. Johnson, L. S. Machado, H. F. Elewa, M. Abdelsaid, D. C. Wiley, and S. C. Fagan Candesartan Augments Ischemia-Induced Proangiogenic State and Results in Sustained Improvement After Stroke Stroke, May 1, 2009; 40(5): 1870 - 1876. [Abstract] [Full Text] [PDF]

				S. Inaba, M. Iwai, M. Furuno, Y. Tomono, H. Kanno, I. Senba, H. Okayama, M. Mogi, J. Higaki, and M. Horiuchi Continuous Activation of Renin-Angiotensin System Impairs Cognitive Function in Renin/Angiotensinogen Transgenic Mice Hypertension, February 1, 2009; 53(2): 356 - 362. [Abstract] [Full Text] [PDF]